A study evaluating the role of docetaxel (Taxotere) in combination with thalidomide in men with hormone refractory prostate cancer

Phase 2

Active, not recruiting

• Conditions: Prostate cancer; Cancer - Prostate

• Registration Number: ACTRN12606000372583
• Lead Sponsor: Royal North Shore Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2004-07-28
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: Male
• Target Recruitment: 35

Inclusion Criteria

1. Histologically/cytologically proven prostate adenocarcinoma2. ALl patients are males, aged 18 years or more and must have prostate adenocarcinoma that is responsive or refractory to hormone therpay.3. Prior treatment with crticosteroids is allowed.4. life expectancy greater or equal to 3 months.5. prior surgery is allowed. At least 4 weeks must have elapsed since the completion of surgery.6. ECOG 0-27. Informed consent signed

Exclusion Criteria

1. Prior cytotoxic chemotherapy (except monotherapy with estramustine)2. prior isotope therapy3. prior radiotherapy to >25% of bone marrow (whole pelvic radiation is not allowed)4. known brain leptomeningeal involvement.5. Other malignancy6. Uncontrolled medical condition7. Prior Deep venous thrombosis or pulmonary embolism

Study & Design

• Study Type: Interventional
• Study Design: Not specified